Della Makower is an Oncology physician affiliated with Albert Einstein College of Medicine. OpenAlex indexes 131 publications with 6,907 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia
Sponsor: Eastern Cooperative Oncology Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20252 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
- Daiichi Sankyo Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
90.4%Aromatase Inhibitor71.6%Anastrozole74%Exemestane16%Letrozole10%Part D≥86 patientsEstrogen Agonist/Antagonist9.9%Tamoxifen Citrate100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
5.3%Serotonin-3 Receptor Antagonist3.6%Ondansetron Hcl100%Part D≥14 patientsH2 blocker1.8%Famotidine100%Part D<11 patientsCardiovascular
4.3%Antiarrhythmic4.3%Lidocaine-Prilocaine100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Montefiore Academic Community NCORP Program
Montefiore Medical Center (bronx, Ny)
FY2026$854,906UG1CA189859
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
Journal of the American Heart Association
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Lipton, MD
Albert Einstein College of Medicine
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine
Jill Crandall, MD
Albert Einstein College of Medicine
Ira Sussman, MD
Albert Einstein College of Medicine
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”